Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Summary

This phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

Conditions

• Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
• Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
• Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
• Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
• Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
• Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
• Childhood Myelodysplastic Syndromes
• Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Disseminated Neuroblastoma
• Malignant Neoplasm
• Ovarian Choriocarcinoma
• Ovarian Embryonal Carcinoma
• Ovarian Immature Teratoma
• Ovarian Mature Teratoma
• Ovarian Mixed Germ Cell Tumor
• Ovarian Monodermal and Highly Specialized Teratoma
• Ovarian Polyembryoma
• Ovarian Yolk Sac Tumor
• Previously Treated Myelodysplastic Syndromes
• Recurrent Adult Acute Lymphoblastic Leukemia
• Recurrent Adult Acute Myeloid Leukemia
• Recurrent Adult Burkitt Lymphoma
• Recurrent Adult Diffuse Large Cell Lymphoma
• Recurrent Adult Diffuse Mixed Cell Lymphoma
• Recurrent Adult Hodgkin Lymphoma
• Recurrent Adult Immunoblastic Large Cell Lymphoma
• Recurrent Adult Lymphoblastic Lymphoma
• Recurrent Grade 3 Follicular Lymphoma
• Recurrent Malignant Testicular Germ Cell Tumor
• Recurrent Mantle Cell Lymphoma
• Recurrent Neuroblastoma
• Recurrent Ovarian Epithelial Cancer
• Recurrent Ovarian Germ Cell Tumor
• Refractory Chronic Lymphocytic Leukemia
• Refractory Multiple Myeloma
• Relapsing Chronic Myelogenous Leukemia
• Stage I Multiple Myeloma
• Stage II Multiple Myeloma
• Stage II Ovarian Epithelial Cancer
• Stage III Malignant Testicular Germ Cell Tumor
• Stage III Multiple Myeloma
• Stage III Ovarian Epithelial Cancer
• Stage IIIA Breast Cancer
• Stage IIIB Breast Cancer
• Stage IIIC Breast Cancer
• Stage IV Breast Cancer
• Stage IV Ovarian Epithelial Cancer
• Testicular Choriocarcinoma
• Testicular Choriocarcinoma and Embryonal Carcinoma
• Testicular Choriocarcinoma and Seminoma
• Testicular Choriocarcinoma and Teratoma
• Testicular Choriocarcinoma and Yolk Sac Tumor
• Testicular Embryonal Carcinoma
• Testicular Embryonal Carcinoma and Seminoma
• Testicular Embryonal Carcinoma and Teratoma
• Testicular Embryonal Carcinoma and Teratoma With Seminoma
• Testicular Embryonal Carcinoma and Yolk Sac Tumor
• Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma
• Testicular Teratoma
• Testicular Yolk Sac Tumor
• Testicular Yolk Sac Tumor and Teratoma
• Testicular Yolk Sac Tumor and Teratoma With Seminoma

Interventions

DRUG

ipilimumab

Given IV

DRUG

therapeutic allogeneic lymphocytes

Given IV

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Ewa Carrier · University of California, San Diego

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2003-04-30

Primary Completion

2008-04-30

Countries

• United States

Study Locations